ArticleTranslational andrology and urology2025
Evaluation of different methods for antibody titre determination in ABO-incompatible kidney transplantation.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ABO-incompatible kidney transplantation: impact of apheresis on graft and patient survival in recipients with low isoagglutinin titer.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Advancing Antibody Titer Assessment in ABO-Incompatible Transplantation.Antibodies (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blood type antibody-mediated rejection is considered the main obstacle to ABO blood type-incompatible kidney transplantation. Choosing an appropriate antibody-level determining method and setting a rational baseline are critical for safely conducting ABO-incompatible kidney allografts. However, due to the differences in antibody detection methods between laboratories, there is no unified baseline to confirm the true titer. Therefore, a generally applicable method must be selected to determine the level of anti-ABO antibodies before surgery, and the actual critical titer level should be set accordingly. This study aims to guide the selection of appropriate antibody titer detection methods for ABO-incompatible kidney transplant recipients by comparing the differences in titer results obtained through various detection methods. Methods: A total of 210 ethylene diamine tetraacetic acid (EDTA)-anticoagulated samples were obtained from patients before or after ABO-I kidney transplantation in our centre. In this study, we tested immunoglobulin M (IgM) and immunoglobulin G (IgG) ABO antibody titres using different detection methods, i.e., a tube test (TT), a microcolumn gel card test (MGT), and a glass bead card test (GBT), to evaluate deviations in antibody levels. Results: According to our results, the IgM titre presented by the TT varied less than one standard dilution from that of the MGT; while the TT resulted in a 2 to 4 titre deviation from that determined by the GBT. For IgG, the titres obtained by the MGT were always one standard dilution higher than those obtained by the TT, and the TT-based and GBT-based titres differed by 2-3 serial dilution steps. Conclusions: It is important that clinical laboratories employ a consistent method of sample testing for a particular patient, and indicate the approach used when reporting results. A further clinical retrospective study revealed that the MGT could effectively monitor titre changes following surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.